TY - JOUR
T1 - Considerations in the Treatment of Tension-Type Headache in the Elderly
AU - Wrobel Goldberg, Stephanie
AU - Silberstein, Stephen
AU - Grosberg, Brian M.
N1 - Funding Information:
Acknowledgments Dr. Silberstein has acted as a consultant and/or advisory panel member for Alder Biopharmaceuticals; Allergan, Inc.; Amgen; Avanir Pharmaceuticals, Inc.; eNeura Inc.; ElectroCore Medical, LLC; Medscape, LLC; Medtronic, Inc.; Mitsubishi Tanabe Pharma America, Inc.; Neuralieve; NINDS; Pfizer, Inc.; Supernus Pharmaceuticals, Inc.; and Teva Pharmaceuticals. His employer receives research support from Allergan, Inc.; Amgen; Cumberland Pharmaceuticals, Inc.; ElectroCore Medical, LLC; Labrys Biologics; Eli Lilly and Company; Merz Pharmaceuticals; and Troy Healthcare. Dr. Wrobel Goldberg has no conflict of interest.
Publisher Copyright:
© 2014, Springer International Publishing Switzerland.
PY - 2014/11
Y1 - 2014/11
N2 - Tension-type headache (TTH) is the most prevalent headache type in all age groups worldwide, including patients with advanced age. Because of its high prevalence and possible association with medical and psychiatric co-morbidities, TTH has a major socioeconomic impact. The lifetime prevalence of TTH ranges between 30 and 78 %, and the 1-year prevalence in individuals over the age of 55 years is 35.8 % (27.8 % in men, 42.4 % in women). Since the prevalence of secondary headache disorders increases in the elderly, the initial evaluation of this group of patients with a new-onset headache or a change in a pre-existing headache pattern should be directed towards their exclusion. This article reviews the diagnostic and treatment dilemmas encountered in elderly patients with tension-type headaches, highlighting both pharmacological and non-pharmacological interventions.
AB - Tension-type headache (TTH) is the most prevalent headache type in all age groups worldwide, including patients with advanced age. Because of its high prevalence and possible association with medical and psychiatric co-morbidities, TTH has a major socioeconomic impact. The lifetime prevalence of TTH ranges between 30 and 78 %, and the 1-year prevalence in individuals over the age of 55 years is 35.8 % (27.8 % in men, 42.4 % in women). Since the prevalence of secondary headache disorders increases in the elderly, the initial evaluation of this group of patients with a new-onset headache or a change in a pre-existing headache pattern should be directed towards their exclusion. This article reviews the diagnostic and treatment dilemmas encountered in elderly patients with tension-type headaches, highlighting both pharmacological and non-pharmacological interventions.
UR - http://www.scopus.com/inward/record.url?scp=84919950299&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84919950299&partnerID=8YFLogxK
U2 - 10.1007/s40266-014-0220-2
DO - 10.1007/s40266-014-0220-2
M3 - Review article
C2 - 25315108
AN - SCOPUS:84919950299
SN - 1170-229X
VL - 31
SP - 797
EP - 804
JO - Drugs and Aging
JF - Drugs and Aging
IS - 11
ER -